CUC (9158) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The most important takeaway from this earnings report is that, although revenue maintained double-digit growth, higher revenue was accompanied by lower profit due to initial losses at newly opened hospice facilities and upfront investment expenses. Revenue was ¥40.17B (+16.2% YoY), Operating Income was ¥3.18B (-30.5%), and Net Income was ¥1.37B (-49.6%). The primary drivers of revenue growth were the opening of 15 new facilities in the hospice business and the expansion of the U.S. business footprint. However, lower utilization rates at new facilities and a temporary reduction in domestic monthly reimbursements pressured earnings.

Factors Affecting Earnings

【Revenue】Revenue was ¥40.17B, up +16.2% year on year. The hospice business drove revenue growth through the opening of 15 new facilities, while Medical Care Residences more than tripled revenue following the consolidation of Noa Conzern. Domestic medical institutions posted an 8.9% year-on-year decline in revenue due to the continuing impact of reduced monthly reimbursements.

【Profit and Loss】Operating Income was ¥3.18B, down -30.5% year on year. The gross profit margin declined to 46.3% from 49.8% last year, while the SG&A expense ratio increased to 40.0%. The primary factors were initial losses at new hospice facilities, the decline in utilization to 46.9%, and the refinement of estimated accounts receivable collection rates in the U.S. business. Net Income was ¥1.37B, down -49.6% year on year, contracting by more than Operating Income. The effective tax rate was high at approximately 49%, and the heavy tax burden further pressured bottom-line profit. In conclusion, revenue increased while profit declined.

Segment Analysis

The hospice business was the largest segment by composition, with revenue of ¥12.28B, and is positioned as the core business. EBITDA for the segment declined 13.2% year on year to ¥1.53B. Initial losses at new facilities and a decline in unit pricing at existing facilities (-5.3%) were the primary reasons for the shortfall against plan, with earnings progress at 46.7%. Domestic medical institutions performed well, with EBITDA of ¥2.70B and earnings progress of 87.1%, whereas U.S. medical institutions significantly underperformed plan, with EBITDA of ¥0.16B and earnings progress of 19.4%. Home-visit nursing was the most stable segment, with EBITDA of ¥1.40B and earnings progress of 90.3%. Overall, the primary drivers of earnings volatility were start-up costs in the core hospice business and delayed monetization of the U.S. business.

Key Financial Indicators

Profitability: ROE 5.7%, Operating Income margin 7.9% (13.2% last year)
Cash quality: Cash and cash equivalents of ¥13.27B, depreciation and amortization expense of ¥3.58B
Investment efficiency: Property, plant and equipment increased +20.3% year on year, indicating a period of growth investment
Financial soundness: Equity Ratio of 32.9% (34.8% last year), long-term borrowings increased +43.2% year on year to ¥29.56B

Cash Flow Analysis

As separate disclosures for Operating Cash Flow (OCF), Investing Cash Flow, and Financing Cash Flow could not be confirmed, the business is evaluated using alternative indicators. EBITDA was approximately ¥6.76B, indicating earnings power including depreciation and amortization expense of ¥3.58B. Cash and cash equivalents increased significantly to ¥13.27B from ¥7.53B in the same period last year. The increase in long-term borrowings (+¥8.91B) was the primary source of financing, with investments in property, plant and equipment (+¥3.83B) and overseas M&A funding appearing to be the main uses of funds. Cash generation is considered standard, but the expansion of assets dependent on borrowings warrants attention.

Earnings Quality

Against Profit Before Tax of ¥2.70B, Net Income was ¥1.37B, with the difference attributable to the ¥1.33B corporate income tax burden. The effective tax rate was high at approximately 49%, exceeding the normal statutory effective tax rate, making it necessary to verify whether temporary tax factors were present. Below Operating Income, financial expenses of ¥0.53B exceeded financial income of ¥0.04B, weighing on Net Income. In the U.S. business, refinement of the estimated accounts receivable collection rate was recorded, with an impact of approximately ¥0.17B. This should be distinguished as a temporary factor based on a change in accounting estimates.

Earnings Forecast and Guidance

Cumulative Q3 progress against the Full-Year forecast was 69.0% for Revenue, 57.8% for Operating Income, and 49.7% for Net Income, below the standard progress rate of 75%. The delays in progress particularly for Operating Income and Net Income reflect start-up costs at new hospice facilities and delayed monetization of the U.S. business. The Company has maintained its Full-Year plan, but substantial profit improvement in Q4 will be required to achieve it. Management explained that it is considering measures including asset securitization.

Shareholder Returns

The Q2 dividend was ¥0 per share, and the Full-Year forecast dividend is also ¥0, indicating that the no-dividend policy remains in place. The Payout Ratio is 0%. As no record of share repurchases could be confirmed, the Total Return Ratio has not been calculated. Given the increase in long-term borrowings and higher leverage, the Company appears likely to allocate retained earnings to investment and debt-related measures for the time being.

Catalysts

【Short Term】Whether the Full-Year plan can be achieved in Q4, and the recovery trend in utilization rates and unit pricing at existing hospice facilities.

【Long Term】The impact of the June 2026 revision to medical service fees, the launch and FY27 monetization of the U.S. OBL business, and progress in roll-up-style M&A in the U.S. podiatry sector.

Industry Benchmarks (For Reference; Compiled by the Company)

Industry Benchmarks (healthcare)

Profitability and Returns

The Operating Income margin exceeds the industry median, while the Net Income margin is below the median, as the tax burden and financial expenses are placing relatively greater pressure on bottom-line profit.

Growth and Capital Efficiency

The Revenue growth rate is at a high level within the industry, with expansion through new facility openings and M&A supporting a pace above the industry average.

※Source: Compiled by the Company

Risk Factors

1. Risk of a shift in the hospice business investment policy: Against the backdrop of uncertainty surrounding the next revision to medical service fees, the Company has temporarily suspended new openings and is transitioning to a multifunctional co-location model (assumed profit margin: 20%). The profit margin of the new model is below that of the previous model (25%).

2. Delayed monetization of the U.S. business: The earnings progress rate of U.S. medical institutions was 19.4%, the lowest among all segments, due to patient seasonality and refinement of the estimated accounts receivable collection rate. Monetization of the OBL business is planned for FY27 and thereafter.

3. High leverage and accounts receivable collection period: Long-term borrowings increased +43.2% year on year to ¥29.56B, and interest-bearing debt was ¥32.96B. Accounts receivable were ¥13.46B, representing 14.0% of total assets, and the length of the collection period represents a working capital burden.

Key Earnings Takeaways

1. Revenue growth and profit decline are occurring simultaneously, clearly indicating a structure in which growth investments—new facility openings and M&A—are pressuring short-term profitability. The key focus going forward will be determining whether this reflects temporary start-up costs or a structural decline in profit margins.

2. The shift in the hospice business investment policy—suspending new openings and transitioning to a multifunctional co-location model—indicates that the focus of business operations is shifting from quantitative expansion toward greater efficiency.

3. Progress against the Full-Year forecast has remained in the 50% range for Operating Income and Net Income, below the standard progress rate. The recovery in profitability in Q4 will be an important point of observation in assessing the quality of the current-period earnings.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,010–¥1,071 at Cost of Equity ±1%, and ¥1,038–¥1,040 at ω±0.1.

Notes:

• Net Income has been significantly compressed relative to Operating Income due to the tax burden, acquisition-related expenses, and non-controlling interests, among other factors (Net Income ÷ Operating Income: 52%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher.
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Goodwill represents a high proportion of net assets, and the assumptions would change significantly if impairment occurs.
• Net assets as of the end of the quarter are used (there is a timing difference from the Full-Year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through an integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---